SAN CARLOS, Calif. & WATERLOO, Ontario--(BUSINESS WIRE)--Onc.AI, a digital health company developing AI-driven oncology clinical management solutions, today announced it has been awarded a $2 million Small Business Innovation Research (SBIR) grant from the National Cancer Institute (NCI). This grant will support the further development and clinical validation of Onc.AI’s advanced imaging-AI software for non-small cell lung cancer (NSCLC) clinical decision-making.

加利福尼亚州圣卡洛斯和安大略省滑铁卢——（商业新闻）——Onc。AI是一家开发AI驱动的肿瘤临床管理解决方案的数字健康公司，今天宣布它已获得美国国家癌症研究所（NCI）200万美元的小企业创新研究（SBIR）资助。这笔赠款将支持Onc的进一步开发和临床验证。AI的用于非小细胞肺癌（NSCLC）临床决策的高级成像AI软件。

The NCI’s SBIR program seeks to accelerate the translation of innovative scientific discoveries into clinical practice, emphasizing the significance of Onc.AI’s work in transforming oncology care..

NCI的SBIR计划旨在加速创新科学发现转化为临床实践，强调Onc的重要性。AI在转变肿瘤护理方面的工作。。

The grant will fund a multi-institutional, prospective clinical study in NSCLC patients using Onc.AI’s AI-based clinical decision support system, which has demonstrated potential in assisting oncologists with assessment of a metastatic NSCLC patient’s likelihood of achieving progression free survival.

该赠款将资助使用Onc的NSCLC患者的多机构前瞻性临床研究。AI基于AI的临床决策支持系统，已证明有潜力帮助肿瘤学家评估转移性NSCLC患者实现无进展生存的可能性。

This initiative builds on the company’s previous success, including results shared at the 2024 American Society of Clinical Oncology (ASCO) meeting, where Onc.AI showcased its adjunctive clinical decision support capabilities from a single pre-treatment CT scan..

这一举措建立在该公司先前成功的基础上，包括在2024年美国临床肿瘤学会（ASCO）会议上分享的结果，Onc在该会议上。AI通过一次治疗前CT扫描展示了其辅助临床决策支持能力。。

Onc.AI’s platform leverages deep learning to extract and quantify complex imaging features that are not visible to the naked eye, revealing insights into the patient’s likelihood of responding to immune checkpoint inhibitor (ICI) monotherapy. By utilizing these subtle radiographic markers, Onc.AI’s solution provides oncologists with more precise information to help guide personalized treatment decisions.

Onc。AI的平台利用深度学习来提取和量化肉眼看不到的复杂成像特征，揭示了患者对免疫检查点抑制剂（ICI）单一疗法反应的可能性。通过利用这些微妙的射线照相标记，Onc。AI的解决方案为肿瘤学家提供了更精确的信息，以帮助指导个性化治疗决策。

This SBIR grant will help the company further validate the AI-based decision support system in clinical settings and expand its potential applications, ultimately supporting oncologists and clinical researchers in improving patient outcomes..

该SBIR拨款将帮助该公司在临床环境中进一步验证基于AI的决策支持系统，并扩展其潜在应用，最终支持肿瘤学家和临床研究人员改善患者预后。。

“Onc.AI’s technology has significant potential in the management of patients with metastatic Non-Small Cell Lung Cancer, I am excited for Ohio State to participate in this study where we aim to evaluate clinical utility prospectively,” said Dwight Owen, MD, MSc, thoracic medical oncologist and member of the translational research team at The James Comprehensive Cancer Center at The Ohio State University in Columbus, OH..

“Onc.AI的技术在治疗转移性非小细胞肺癌患者方面具有巨大潜力，我很高兴俄亥俄州能够参加这项研究，我们的目标是前瞻性地评估临床效用，”俄亥俄州立大学哥伦布分校詹姆斯综合癌症中心胸科肿瘤学家兼转化研究团队成员Dwight Owen博士说。。

“We are honored and thankful for the recognition from the NCI,” added Petr Jordan, Chief Technical Officer of Onc.AI “We are excited about the progress we have made so far and this grant enables us to further refine our technology and explore additional applications of our foundational deep learning radiomics biomarker technology that improve upon existing standard of care tools that support oncologist decision-making.”.

Onc首席技术官彼得·乔丹（PetrJordan）补充道：“我们很荣幸并感谢NCI的认可。”。AI“我们对迄今为止取得的进展感到兴奋，这项拨款使我们能够进一步完善我们的技术，并探索我们的基础深度学习放射组学生物标志物技术的其他应用，这些技术改进了支持肿瘤学家决策的现有标准护理工具。”。

About Onc.AI

关于Onc。AI

Onc.AI is a privately held digital health company developing a precision oncology clinical management platform with the goal of transforming clinical decision-making. Onc.AI was founded based on a simple idea: radiomics-based machine learning models can radically improve the ability to predict patient response to PD-(L)1 immunotherapy.

Onc。AI是一家私营数字健康公司，开发精确的肿瘤临床管理平台，旨在改变临床决策。Onc。AI是基于一个简单的想法建立的：基于放射组学的机器学习模型可以从根本上提高预测患者对PD-（L）1免疫疗法反应的能力。

Onc.AI aims to develop a first-in-class radiomic solution to address the unpredictable response and non-response to PD-(L)1 ICI therapy to improve outcomes for patients and reduce the cost burden on healthcare systems and public/private payers..

Onc。AI旨在开发一流的放射学解决方案，以解决PD-（L）1 ICI治疗的不可预测反应和无反应，从而改善患者的预后，减轻医疗保健系统和公共/私人付款人的成本负担。。